Agendia Presents New Data Demonstrating Clinical Utility for MammaPrint and BluePrint at the 2020 European Breast Cancer Conference Virtual Event

Presentations to include follow-up MINDACT study data and evaluations on the use of MammaPrint to guide treatment decisions in lobular cancers and for screen-detected breast cancers versus interval-detected breast cancers IRVINE, Calif., Oct. 2, 2020 /PRNewswire/ -- Agendia, Inc., a world...

from PR Newswire: https://ift.tt/3irrsmC